Duchenne News Tags: Antisense Therapeutics

June 8, 2023
Antisense Therapeutics announces that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne.
May 23, 2023
Antisense announces approval to conduct phase 2b trial of ATL1102 and appoints CEO Dr. James Garner

Accessible Vehicle Fund Applications Open